Clinical trials on Hepatic Impairment

Hepatic Impairment: An Overview

Hepatic impairment, commonly referred to as liver dysfunction, is a condition where the liver’s ability to perform its vital functions is compromised. The liver, a key player in the body’s metabolic processes, is responsible for detoxifying harmful substances, aiding in digestion through bile production, and storing essential nutrients. When impaired, these critical functions can be significantly affected, leading to a range of health issues. Hepatic impairment can result from various factors, including chronic alcohol abuse, viral hepatitis, fatty liver disease, and exposure to toxic substances.

The severity of hepatic impairment is often categorized into different stages, from mild dysfunction, which may present minimal to no symptoms, to severe liver damage, such as cirrhosis or liver failure, which can be life-threatening. Symptoms of liver impairment can vary widely but may include jaundice (yellowing of the skin and eyes), fatigue, weakness, and swelling in the legs and abdomen due to fluid accumulation. Diagnosis typically involves a combination of medical history, physical examination, and various tests such as liver function tests, imaging studies, and sometimes liver biopsy.

Management and treatment of hepatic impairment depend on the underlying cause and the severity of the condition. Lifestyle modifications, such as abstaining from alcohol, maintaining a healthy weight, and following a balanced diet, are crucial in all stages of liver impairment. Medications may be prescribed to treat specific causes of liver damage, such as antiviral drugs for hepatitis or medications to control liver inflammation. In severe cases, where the liver is extensively damaged, a liver transplant may be considered the only viable treatment option. Early detection and appropriate management are key to preventing the progression of liver disease and improving quality of life.

  • CT-EU-00054006

    Understanding Tazemetostat’s impact in cancer patients with liver conditions

    This trial assesses tazemetostat, focusing on how it’s processed in the body (pharmacokinetics) and its safety. Participants with advanced cancers and either normal liver function or liver impairment take the drug, and researchers compare how their bodies respond. The goal is to understand how liver health affects tazemetostat treatment in cancer patients.

    • Tazemetostat